Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3234
Name central nervous system lymphoma
Definition A hematologic cancer that has_material_basis_in lymphoma located_in central nervous system.
Source DiseaseOntology.org
Alt Ids DOID:3233
Path disease disease of cellular proliferation cancer organ system cancer nervous system cancer central nervous system cancer central nervous system lymphoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00267865 Phase II Rituximab Methotrexate Leucovorin Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma Completed USA 0
NCT00293475 Phase Ib/II Carboplatin + Mannitol + Methotrexate + Rituximab Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Active, not recruiting USA 0
NCT00621036 Phase II Methotrexate Thiotepa Sargramostim Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Withdrawn USA 0
NCT02203526 Phase I Dexamethasone + Etoposide + Ibrutinib + Pegylated liposomal-doxorubicin + Temozolomide Cytarabine Rituximab Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma Recruiting USA 0
NCT02301364 Phase II Buparlisib Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) Completed USA 0
NCT02315326 Phase Ib/II Ibrutinib Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) Recruiting USA 0
NCT02498951 Phase II Obinutuzumab Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response Recruiting USA 0
NCT02669511 Phase II PQR309 PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Completed 0
NCT02857426 Phase II Nivolumab A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) (CheckMate 647) Completed USA | ITA | FRA | DEU | CAN 8
NCT03220646 Phase II Abemaciclib Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors Active, not recruiting USA 0
NCT03484702 Phase II Lisocabtagene maraleucel Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCENDWORLD) Active, not recruiting ITA | FRA | ESP | DEU | BEL | AUT 5
NCT03558750 Phase Ib/II Lenalidomide + Nivolumab + Rituximab Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma Terminated USA 0
NCT03581942 Phase Ib/II Copanlisib + Ibrutinib Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) Recruiting USA 0
NCT03684980 Phase I Glucarpidase + Leucovorin + Methotrexate + Rituximab LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma - ARM A Recruiting USA 0
NCT03703167 Phase I Ibrutinib + Lenalidomide + Rituximab Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) Active, not recruiting USA 0
NCT03770416 Phase II Ibrutinib + Nivolumab Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma Recruiting USA 0
NCT03964090 Phase II Cytarabine + Dexamethasone + Etoposide + Isavuconazole + Pegylated liposomal-doxorubicin + Rituximab + Temozolomide Cytarabine + Dexamethasone + Etoposide + Ibrutinib + Isavuconazole + Pegylated liposomal-doxorubicin + Rituximab + Temozolomide Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) Recruiting USA 0
NCT04073147 Phase I Obinutuzumab + Venetoclax Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma (VENOBI-CNS) Terminated DEU 0
NCT04134117 Phase I Tisagenlecleucel Tisagenlecleucel In Primary CNS Lymphoma Recruiting USA 0
NCT04401774 Phase II Nivolumab Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy Recruiting USA 0
NCT04421560 Phase Ib/II Ibrutinib + Pembrolizumab + Rituximab Pembrolizumab, Ibrutinib and Rituximab in PCNSL Recruiting USA 0
NCT04446962 Phase Ib/II Ibrutinib Lenalidomide LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) (LOC-R01) Recruiting FRA 0
NCT04462328 Phase I Acalabrutinib + Durvalumab Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma Recruiting USA 0
NCT04548648 Phase II Acalabrutinib Isavuconazole LCCC1841: A Phase 2 Trial of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas Recruiting USA 0
NCT04608487 Phase I Cyclophosphamide + Fludarabine axicabtagene ciloleucel Axi-cel in CNS Lymphoma Recruiting USA 0
NCT04609046 Phase I Lenalidomide + Nivolumab Lenalidomide + Methotrexate + Nivolumab + Rituximab Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma Recruiting USA 0
NCT04906096 Phase II GDC-0084 Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL Recruiting USA 0
NCT04906902 Phase Ib/II Acalabrutinib Acalabrutinib in CNSL Recruiting USA 0
NCT04931368 Phase III Cytarabine + Methotrexate + Rituximab + Thiotepa OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma (OptiMATe) Recruiting DEU 0
NCT04947319 Phase II Tirabrutinib Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Recruiting USA 0
NCT05131022 Phase I NX-5948 Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting 1
NCT05211336 Phase I Lenalidomide + Nivolumab Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid With Nivolumab (VIPOR-Nivo) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System Suspended USA 0
NCT05242146 Phase Ib/II GB5121 GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma (STAR CNS) Recruiting USA | FRA 2
NCT05351593 Phase Ib/II Lenalidomide + Tafasitamab-cxix Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma Recruiting USA 0